Consenso sarcopenia IA Flashcards

1
Q

What is sarcopenia?

A

A progressive and generalised skeletal muscle disorder associated with increased likelihood of adverse outcomes including falls, fractures, physical disability and mortality.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the main health risks associated with untreated sarcopenia?

A
  • Increased risk of falls and fractures
  • Impaired ability to perform activities of daily living
  • Associated with cardiac disease
  • Associated with respiratory disease
  • Associated with cognitive impairment
  • Leads to mobility disorders
  • Contributes to lowered quality of life
  • Loss of independence or need for long-term care placement
  • Increased mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How does sarcopenia affect healthcare costs?

A

Sarcopenia increases risk for hospitalisation and raises the cost of care during hospitalisation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

How much more likely are older adults with sarcopenia to incur higher hospital costs compared to those without?

A

More than 5-fold more likely.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the key insights from EWGSOP2 regarding sarcopenia?

A
  • Development of sarcopenia begins earlier in life
  • Sarcopenia is now considered a muscle disease (muscle failure)
  • Low muscle strength is a principal determinant
  • Muscle mass and quality are mainly used in research, not clinical practice
  • Sarcopenia is often overlooked and undertreated in mainstream practice
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the primary parameter for diagnosing sarcopenia according to EWGSOP2?

A

Low muscle strength.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What criteria must be met to diagnose sarcopenia as severe?

A
  • Low muscle strength
  • Low muscle quantity or quality
  • Low physical performance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the SARC-F questionnaire used for?

A

To elicit self-reports from patients on signs characteristic of sarcopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the recommended method for case-finding in clinical practice for sarcopenia?

A

Use of the SARC-F questionnaire.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the three criteria for identifying probable sarcopenia?

A
  • Low muscle strength
  • Low muscle quantity or quality
  • Low physical performance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

True or False: Sarcopenia is primarily a condition associated only with older adults.

A

False.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the implications of identifying sarcopenia earlier in life?

A

It opens up opportunities for interventions that can prevent or delay the development of sarcopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What factors contribute to the complexity of diagnosing sarcopenia?

A
  • Determining what variables to measure
  • How to measure them
  • What cut-off points guide diagnosis and treatment
  • Evaluating effects of therapeutic interventions
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What does the term ‘muscle quality’ refer to in the context of sarcopenia?

A

Micro- and macroscopic aspects of muscle architecture and composition.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the recommended tools for measuring muscle strength in clinical practice?

A
  • Grip strength test
  • Chair stand test
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the significance of muscle strength in predicting adverse outcomes related to sarcopenia?

A

Muscle strength is recognized as a better predictor of adverse outcomes than muscle mass.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Fill in the blank: Sarcopenia is often overlooked and ______ in mainstream practice.

A

undertreated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What are the potential drivers of disability in activities of daily living (ADL) associated with sarcopenia?

A
  • Lower gait speed
  • Chair stand performance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the aim of the EWGSOP2 updates regarding sarcopenia?

A
  • Build a sarcopenia definition reflecting recent advances
  • Identify variables that best detect sarcopenia
  • Advise cut-off points for measured variables
  • Recommend an updated screening and assessment pathway
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What is the advantage of using the Ishii screening test?

A

It estimates the probability of sarcopenia using an equation-derived score based on age, grip strength, and calf circumference.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How does low physical performance relate to sarcopenia?

A

Detection of low physical performance predicts adverse outcomes and is used to identify the severity of sarcopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the role of the European Geriatric Medicine Society (EuGMS) concerning EWGSOP2?

A

Organized EWGSOP2 and included experts to update sarcopenia definitions and diagnostic characteristics.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is SARC-F?

A

A self-reported screening tool reflecting patient perceptions of adverse outcomes

SARC-F is used in multiple languages to assess the risk of sarcopenia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the Ishii screening test used for?

A

To estimate the probability of sarcopenia using age, grip strength, and calf circumference

It is a more formal case-finding instrument preferred in clinical settings.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Why is grip strength an important measure?

A

It predicts poor patient outcomes such as longer hospital stays and increased functional limitations

Low grip strength is associated with poor health-related quality of life and death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What equipment is commonly used to measure grip strength?

A

The Jamar dynamometer

Other brands are being explored but Jamar is widely validated.

27
Q

What does the chair stand test measure?

A

Strength of leg muscles, specifically the quadriceps muscle group

It assesses the time taken to rise from a seated position multiple times.

28
Q

How can muscle quantity be estimated?

A

Using techniques like MRI, CT, DXA, and BIA

Muscle quantity can be reported as total body Skeletal Muscle Mass (SMM) or Appendicular Skeletal Muscle Mass (ASM).

29
Q

What are gold standards for non-invasive assessment of muscle quantity?

A

MRI and CT

They are high-cost and require trained personnel, limiting their use in primary care.

30
Q

What does DXA measure?

A

Total body lean tissue mass or appendicular skeletal muscle mass non-invasively

DXA results can vary between brands, affecting consistency.

31
Q

What is bioelectrical impedance analysis (BIA) used for?

A

To estimate total or appendicular skeletal muscle mass based on body electrical conductivity

BIA is affordable and portable but requires careful calibration.

32
Q

What does muscle quality refer to?

A

Micro- and macroscopic changes in muscle architecture and function per unit of muscle mass

It is assessed using imaging tools and strength-to-mass ratios.

33
Q

What is the creatine dilution test?

A

A method to estimate whole-body muscle mass using deuterium-labelled creatine

It correlates well with MRI measures of muscle mass.

34
Q

What is the significance of gait speed in assessing sarcopenia?

A

It is a reliable predictor of adverse outcomes related to sarcopenia such as disability and mortality

A cut-off speed of ≤0.8 m/s indicates severe sarcopenia.

35
Q

What does the Short Physical Performance Battery (SPPB) assess?

A

Gait speed, balance, and chair stand performance

A score of ≤8 points indicates poor physical performance.

36
Q

What is the purpose of the Timed-Up and Go test (TUG)?

A

To evaluate physical function through a series of movements

The test involves rising from a chair, walking to a marker, and sitting down.

37
Q

What is the role of specific biomarkers in diagnosing sarcopenia?

A

To identify and monitor the condition through markers related to muscle function and inflammation

A panel of biomarkers may be more effective than a single biomarker due to the complexity of sarcopenia.

38
Q

What is the advantage of using ultrasound for muscle assessment?

A

It provides reliable measures of muscle quantity and quality

Ultrasound can detect changes in muscle thickness and cross-sectional area efficiently.

39
Q

What does calf circumference predict in older adults?

A

Performance and survival

A calf circumference cut-off point of <31 cm is significant.

40
Q

What does muscle strength correlate with?

A

Strength in other body compartments

Grip strength serves as a surrogate for more complicated strength measures.

41
Q

What is the disadvantage of DXA?

A

It is not portable for community use

DXA measurements can also be influenced by patient hydration status.

42
Q

What is sarcopenia?

A

A muscle disease rooted in adverse muscle changes that accrue across a lifetime

43
Q

What is the main indicator of probable sarcopenia according to EWGSOP2?

A

Low strength

44
Q

How is sarcopenia categorized based on duration?

A

Acute (<6 months) and chronic (≥6 months)

45
Q

What does the SarQoL tool assess?

A

Patients’ perception of physical, psychological, and social aspects of health

46
Q

What are the three parameters defining sarcopenia?

A
  • Muscle strength
  • Muscle quantity/quality
  • Physical performance
47
Q

Which questionnaire is recommended for finding individuals with probable sarcopenia?

A

SARC-F questionnaire

48
Q

What is the recommended pathway for sarcopenia case-finding?

A

Find-Assess-Confirm-Severity (F-A-C-S)

49
Q

What is the relationship between aging and muscle mass?

A

Muscle mass generally increases in youth, is maintained in midlife, and decreases with aging

50
Q

What factors can contribute to the development of sarcopenia?

A
  • Aging
  • Inadequate energy or protein intake
  • Physical inactivity
  • Systemic diseases
51
Q

What type of studies are needed to validate the sensitivity of SarQoL?

A

Longitudinal studies

52
Q

What are the EWGSOP2 recommendations for cut-off points based on?

A

European populations and normative references

53
Q

What is sarcopenic obesity?

A

Reduced lean body mass in the context of excess adiposity

54
Q

What is the distinction between primary and secondary sarcopenia?

A
  • Primary: Age-related with no other specific cause
  • Secondary: Due to other causes, such as systemic disease
55
Q

True or False: Sarcopenia can occur due to malnutrition.

56
Q

What is the significance of grip strength in sarcopenia assessment?

A

It is a key measure of muscle strength

57
Q

Fill in the blank: Sarcopenia is defined by low levels of muscle strength, muscle ______, and physical performance.

A

quantity/quality

58
Q

What should be done to prevent or delay sarcopenia?

A

Maximize muscle in youth, maintain muscle in middle age, minimize loss in older age

59
Q

What are some suggested areas for further research in sarcopenia?

A
  • Influences causing sarcopenia
  • Identification of high-risk individuals
  • Validated cut-off points
  • Muscle quality indicators
60
Q

What is frailty characterized by?

A

Cumulative decline in multiple body systems or functions

61
Q

What overlap exists between frailty and sarcopenia?

A

Low grip strength and slow gait speed

62
Q

What are the current EWGSOP2 cut-off points for grip strength in men?

63
Q

What is one of the primary goals of the updated recommendations by EWGSOP2?

A

Facilitate early detection and better treatment of sarcopenia

64
Q

What is a challenge in the research and development of sarcopenia?

A

Lack of consistency due to disputes over cut-off points